Nash Drug Developers Fall As Lilly's Weight: loss drug shows promise in trial

89bio

06/02/2024 16:42

(Updates)
    ** Shares of companies developing NASH treatments fall 
after Eli Lilly's  LLY.N  weight-loss drug met main goal of
mid-stage trial in patients with fatty liver disease 
    ** LLY said Tuesday that tirzepatide helped 73.9% of
patients achieve "absence of the disease" at 52 weeks
    ** Nonalcoholic steatohepatitis (NASH) is a type of fatty
liver disease with no approved treatments in the market 
    ** Shares of Madrigal Pharmaceuticals  MDGL.O , which is
seeking U.S. FDA approval for its NASH drug, fall to over
two-month low of $171.3
    ** Shares of rival Akero Therapeutics  AKRO.O  fall to
almost two-month low of $15.32
    ** Shares of other NASH drug developers such as NeuroBo
Pharmaceuticals  NRBO.O  and 89bio Inc  ETNB.O  fall 12.4% to
$4.38 and 23.8% to over two-month low of $7.47, respectively

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com))